Home Newsfeeds FingerMotion Q1 Sales $4.86M

FingerMotion Q1 Sales $4.86M

FingerMotion (NASDAQ:FNGR) reported $4.86 million in sales this quarter.

byBenzinga Newsdesk

July 18, 2022

1 minute read

FingerMotion (NASDAQ:FNGR) reported $4.86 million in sales this quarter.

Tesla Bull Shrugs Off Current Phase As ‘Pause Into Next Phase Of Growth Story,’ Calls UAW Strike A ‘Win-Win’ For EV Maker

By Shanthi Rexaline

October 4, 3:19 AM

Tesla's Q3 deliveries miss does not deter this analyst from owning and recommending the stock as he believes this is a pause before a takeoff.

BYDDF

Events
News

Merck Announced Five-Year Data for KEYTRUDA Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer

By Charles Gross

September 11, 11:33 AM

Five-year overall survival rate of 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials

MRK

AI Wants You To Know Who Is Boss: GitHub Automod Bans Its Own Maker

By Rounak Jain

February 6, 4:31 AM

In an irony of sorts, co-founder of GitHub, Chris Wanstrath "defunkt" has announced his ban from GitHub and plans to shift to BitBucket.

MSFT

Coca-Cola, Microsoft And 3 Stocks To Watch Heading Into Wednesday

By Lisa Levin

July 26, 4:16 AM

With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

FingerMotion Q1 Sales $4.86M

Related Posts

Tesla Bull Shrugs Off Current Phase As ‘Pause Into Next Phase Of Growth Story,’ Calls UAW Strike A ‘Win-Win’ For EV Maker

Merck Announced Five-Year Data for KEYTRUDA Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer

AI Wants You To Know Who Is Boss: GitHub Automod Bans Its Own Maker

Coca-Cola, Microsoft And 3 Stocks To Watch Heading Into Wednesday